Related references
Note: Only part of the references are listed.Gefitinib-loaded starch nanoparticles for battling lung cancer: Optimization by full factorial design and in vitro cytotoxicity evaluation
Haitham Amin et al.
SAUDI PHARMACEUTICAL JOURNAL (2023)
Physicochemical Characterizations and Pharmacokinetic Evaluation of Pentazocine Solid Lipid Nanoparticles against Inflammatory Pain Model
Zaheer Ullah Khan et al.
PHARMACEUTICS (2022)
Supersaturation-Based Drug Delivery Systems: Strategy for Bioavailability Enhancement of Poorly Water-Soluble Drugs
Arvind Sharma et al.
MOLECULES (2022)
PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer
Abdelrahman Y. Sherif et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2022)
Nanocrystallization Improves the Solubilization and Cytotoxic Effect of a Poly (ADP-Ribose)-Polymerase-I Inhibitor
Amer S. Alali et al.
POLYMERS (2022)
Boosting the Anticancer Activity of Sunitinib Malate in Breast Cancer through Lipid Polymer Hybrid Nanoparticles Approach
Mohammed Muqtader Ahmed et al.
POLYMERS (2022)
Raloxifene potentiates the effect of gefitinib in triple-negative breast cancer cell lines
Sebastien Taurin et al.
MEDICAL ONCOLOGY (2022)
Development and Evaluation of Repurposed Etoricoxib Loaded Nanoemulsion for Improving Anticancer Activities against Lung Cancer Cells
Shadab Md et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Intranasal delivery of Naloxone-loaded solid lipid nanoparticles as a promising simple and non-invasive approach for the management of opioid overdose
Nazeer Hasan et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2021)
Gefitinib loaded PLGA and chitosan coated PLGA nanoparticles with magnified cytotoxicity against A549 lung cancer cell lines
Abdullah S. Alshetaili
SAUDI JOURNAL OF BIOLOGICAL SCIENCES (2021)
p28-functionalized PLGA nanoparticles loaded with gefitinib reduce tumor burden and metastases formation on lung cancer
Ana Rita Garizo et al.
JOURNAL OF CONTROLLED RELEASE (2021)
Topical nanostructured lipid carrier gel of quercetin and resveratrol: Formulation, optimization, in vitro and ex vivo study for the treatment of skin cancer
Mohammad Imran et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2020)
Eluxadoline Loaded Solid Lipid Nanoparticles for Improved Colon Targeting in Rat Model of Ulcerative Colitis
Md. Khalid Anwer et al.
PHARMACEUTICALS (2020)
Gefitinib encapsulation based on nano-liposomes for enhancing the curative effect of lung cancer
Yanjie Hu et al.
CELL CYCLE (2020)
Controlled release alginate-chitosan microspheres of tolmetin sodium prepared by internal gelation technique and characterized by response surface modeling
Mahmoud M. A. Elsayed
BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats
Khalid Anwer et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2019)
Solution Stability of Poloxamer 188 Under Stress Conditions
Tingting Wang et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Investigation of inclusion behaviour of gefitinib with epichlorohydrin-beta-cyclodextrin polymer: preparation of binary complex, stoichiometric determination and characterization
Bina Gidwani et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2018)
Gefitinib-loaded DSPE-PEG2000 nanomicelles with CD133 aptamers target lung cancer stem cells
Xiaolong Huang et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2017)
Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines
Nesstor Pilco-Ferreto et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
Abderrahim El Guerrab et al.
ONCOTARGET (2016)
Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer
Leilei Fu et al.
SCIENTIFIC REPORTS (2016)
Preparation and Characterization of Loperamide-Loaded Dynasan 114 Solid Lipid Nanoparticles for Increased Oral Absorption In the Treatment of Diarrhea
Lili Wei et al.
FRONTIERS IN PHARMACOLOGY (2016)
Characterization, biorecognitive activity and stability of WGA grafted lipid nanostructures for the controlled delivery of Rifampicin
Deep Pooja et al.
CHEMISTRY AND PHYSICS OF LIPIDS (2015)
/In vitro cytotoxicity analysis of doxorubicinloaded/superparamagnetic iron oxide colloidal nanoassemblies on MCF7 and NIH3T3 cell lines
Katerina Tomankova et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2015)
Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression
Xia Zhang et al.
SCIENTIFIC REPORTS (2015)
Preparation and characterisation of Kolliphor® P 188 and P 237 solid dispersion oral tablets containing the poorly water soluble drug disulfiram
Nisrina Ramadhani et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2014)
Gefitinib loaded folate decorated bovine serum albumin conjugated carboxymethyl-beta-cyclodextrin nanoparticles enhance drug delivery and attenuate autophagy in folate receptor-positive cancer cells
Yijie Shi et al.
JOURNAL OF NANOBIOTECHNOLOGY (2014)
Development and Evaluation of Solid Lipid Nanoparticles of Raloxifene Hydrochloride for Enhanced Bioavailability
Anand Kumar Kushwaha et al.
BIOMED RESEARCH INTERNATIONAL (2013)
The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
A. A. Armour et al.
EUROPEAN RESPIRATORY REVIEW (2010)
Gefitinib Induces Apoptosis and Decreases Telomerase Activity in MDA-MB-231 Human Breast Cancer Cells
Dong-Oh Moon et al.
ARCHIVES OF PHARMACAL RESEARCH (2009)
EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer
David E. Gerber
DRUG DEVELOPMENT RESEARCH (2008)
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib
N Normanno et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors
G Blackledge et al.
BRITISH JOURNAL OF CANCER (2004)
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
R Sordella et al.
SCIENCE (2004)
Micellar nanocontainers distribute to defined cytoplasmic organelles
R Savic et al.
SCIENCE (2003)
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro
JMW Gee et al.
ENDOCRINOLOGY (2003)
Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN) -: effect of surfactants, storage time and crystallinity
C Olbrich et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2002)
Share Paper
